Fig. 5

The pharmacokinetics and pharmacodynamics of BsAb-armed T cells. A Schematic of the pharmacokinetics experiment on BsAb-armed T cells. B 1 × 10⁷ T cells or BsAb-armed T cells were administered intravenously into SCID mice. Blood samples were collected at consecutive time points. The white blood cells were isolated from the blood by red blood cell lysis. The pharmacokinetics of BsAb-armed T cells were determined as CD3⁺ BsAb⁺ T cells and analyzed by flow cytometry. C Schematic of the BsAbs in vivo half-life analysis. The BsAb or human IgG was administered intravenously to C57BL/6 mice. Blood samples were collected at consecutive time points, and the serum concentrations of D anti-PSMA/anti-CD3 (Fab-scFv), E anti-PSMA/anti-CD3(scFv-Fab) BsAb, and F human IgG were quantified by sandwich ELISA. G The half-life of BsAbs in SCID mice. H–K The pharmacodynamics of BsAb-armed T cells: 1 × 10⁷ NIR-797-labeled T cells or BsAb-armed T cells were intravenously injected into LNCaP (100 mm³) bearing SCID mice. H The whole body was imaged 24 h post-injection with an IVIS spectrum imaging system. I The fluorescent intensity in tumors was analyzed with Living Image software (version 2.50). After mice were sacrificed 24 h post-injection, their J tumor and K organs were isolated for imaging with an IVIS spectrum imaging system to quantify their fluorescent signal. Bar, SD; *p < 0.05; **p < 0.01; ***p < 0.001